VYNE Therapeutics Inc

Research VYNE Therapeutics Inc (VYNE) on Bullrun: market cap USD 21.60M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVYNE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 21.60M
• Financial periodFY2025
• RevenueUSD 570.00K
• Revenue growth13.8%
• Net income-USD 26.48M
• Free cash flow-USD 33.12M

Valuation Snapshot

latest market cap is USD 21.60M.

About VYNE Therapeutics Inc

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure.

Frequently asked questions

What is VYNE Therapeutics Inc's market cap?

VYNE Therapeutics Inc's market capitalization is USD 21.60M.

What does VYNE Therapeutics Inc do?

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.